Skip to main content

Elinzanetant Efficacious, Well-Tolerated for Vasomotor Symptoms

Medically reviewed by Carmen Pope, BPharm. Last updated on Aug 27, 2024.

By Elana Gotkine HealthDay Reporter

TUESDAY, Aug. 27, 2024 -- For menopausal vasomotor symptoms (VMS), elinzanetant is efficacious and well-tolerated, according to a study published online Aug. 22 in the Journal of the American Medical Association.

JoAnn V. Pinkerton, M.D., from the University of Virginia Health in Charlottesville, and colleagues examined the efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist, for the treatment of moderate-to-severe menopausal VMS in two randomized, double-blind, phase 3 trials (OASIS 1 and 2), including postmenopausal participants aged 40 to 65 years. Eligible participants were randomly assigned to elinzanetant 120 mg for 26 weeks (199 and 200 in OASIS 1 and 2, respectively) or matching placebo for 12 weeks followed by elinzanetant 120 mg for 14 weeks (197 and 200 in OASIS 1 and 2, respectively).

The researchers found a significant reduction in VMS frequency with elinzanetant at week 4 (−3.3 and −3.0 in OASIS 1 and 2, respectively) and week 12 (−3.2 and −3.2 in OASIS 1 and 2, respectively). In addition, the severity of VMS was improved with elinzanetant at week 4 (−0.3 and −0.2 in OASIS 1 and 2, respectively) and week 12 (−0.4 and −0.3 in OASIS 1 and 2, respectively). Improvement in sleep disturbances and menopause-related quality of life was seen with elinzanetant at week 12, and the safety profile was favorable.

"Elinzanetant has the potential to provide a well-tolerated and efficacious nonhormonal treatment option to address the unmet health needs of many menopausal individuals with moderate-to-severe VMS," the authors write.

Several authors disclosed ties to pharmaceutical companies, including Bayer, which manufactures elinzanetant and funded the OASIS 1 and 2 trials.

Abstract/Full Text

Editorial

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Air Pollution May Worsen Bone Health in Postmenopausal Women

FRIDAY, May 16, 2025 -- Exposure to air pollution may worsen bone loss in postmenopausal women, according to a study published online April 24 in the Journal of Bone and...

More Research Needed to Prepare People With Mental Illness for Menopause

THURSDAY, May 15, 2025 -- Few studies examine how people living with a mental illness may be best prepared for the menopause transition, considering both menopause symptoms and...

Hormone Therapy Tied to Worse Bladder Health in Postmenopausal Women

TUESDAY, May 6, 2025 -- Hormone therapy use is linked to worse bladder health in postmenopausal women, according to a study published online April 29 in Menopause. Camille...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.